Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
暂无分享,去创建一个
P. Hotez | J. Pollet | M. Bottazzi | Zhuyun Liu | Wen-Hsiang Chen | B. Zhan | U. Strych | B. Keegan | Cristina Poveda | M. Reers | S. Ronca | L. Versteeg | Jungsoon Lee | Maria José Villar | R. Adhikari | Junfei Wei | P. Gillespie | J. Kimata | V. Paradkar | R. Kundu | S. Thimmiraju | B. Lopez | Leroy Versteeg
[1] G. Medigeshi,et al. Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies , 2022, medRxiv.
[2] Gregory D. Gromowski,et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates , 2021, Science Translational Medicine.
[3] Gregory D. Gromowski,et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge , 2021, NPJ vaccines.
[4] G. Screaton,et al. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies , 2021, bioRxiv.
[5] P. Hotez,et al. Restoring Vaccine Diplomacy. , 2021, JAMA.
[6] Gregory D. Gromowski,et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity , 2021, bioRxiv.
[7] M. Nussenzweig,et al. Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection , 2021, bioRxiv.
[8] B. Pulendran,et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.
[9] P. Hotez,et al. SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice , 2021, Human vaccines & immunotherapeutics.
[10] D. Ho,et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques , 2021, bioRxiv.
[11] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[12] Yan Liu,et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.
[13] K. Makar,et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.
[14] M. Nussenzweig,et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice , 2020, Science.
[15] P. Hotez,et al. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1 , 2020, Applied Microbiology and Biotechnology.
[16] J. Pollet,et al. Recombinant protein vaccines, a proven approach against coronavirus pandemics , 2020, Advanced Drug Delivery Reviews.
[17] P. Hotez,et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate , 2020, Biochimica et Biophysica Acta (BBA) - General Subjects.
[18] R. Owens,et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses , 2020, Nature Communications.
[19] P. Hotez,et al. Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement , 2020, bioRxiv.
[20] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[21] Kevin S. Naceanceno,et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen , 2018, Vaccine.
[22] P. Hotez,et al. New Vaccines for the World's Poorest People. , 2016, Annual review of medicine.
[23] D. Klinman,et al. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. , 2014, Vaccine.
[24] A. Jakubowska,et al. CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice , 2004, Clinical Cancer Research.
[25] Luigi Naldini,et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.
[26] D O Morgan,et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.
[27] D. Klinman,et al. CpG Oligonucleotides as Vaccine Adjuvants. , 2021, Methods in molecular biology.
[28] A. Sigal,et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021 .
[29] John D Campbell,et al. Development of the CpG Adjuvant 1018: A Case Study. , 2017, Methods in molecular biology.
[30] Xavier le Guezennec,et al. Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants. , 2017, Journal of immunological methods.